Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: Department of Health and Human Services | Clear Filter
Summary:The CDC Vaccine Committee ended its Hepatitis B vaccine recommendation for babies, a decision applauded given that the majority of babies are not at risk for Hepatitis B, a disease primarily transmitted sexually or through dirty needles. The American Childhood Vaccine Schedule, which includes 72 "jabs" for healthy babies, is deemed excessive and ridiculed for being far more extensive than schedules in other countries. A Presidential Memorandum has been signed, directing the Department of Health and Human Services to "FAST TRACK" a comprehensive evaluation of global vaccine schedules to align the U.S. schedule with the "Gold Standard of Science and COMMON SENSE." Confidence is expressed that Secretary Robert F. Kennedy, Jr., and the CDC will execute this directive effectively for the nation's children.
Sentiment:Directive
Key Claims:
- The CDC Vaccine Committee ended its Hepatitis B vaccine recommendation for babies.
- The vast majority of babies are at no risk of Hepatitis B.
- Hepatitis B is mostly transmitted sexually or through dirty needles.
- The American Childhood Vaccine Schedule requires 72 "jabs" for perfectly healthy babies.
- The U.S. vaccine schedule is far more extensive than any other country's and more than necessary.
- The U.S. vaccine schedule is "ridiculous."
- Many parents and scientists have questioned the efficacy of the U.S. vaccine schedule.
- A Presidential Memorandum has been signed, directing HHS to "FAST TRACK" a comprehensive evaluation of global vaccine schedules.
- The goal is to better align the U.S. Vaccine Schedule with the "Gold Standard of Science and COMMON SENSE."
- Secretary Robert F. Kennedy, Jr., and the CDC are expected to accomplish this quickly and correctly.
Potential Market Impact (S&P 500):3/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:3/10
« Previous
Page 1 of 1
Next »